Chronic leukaemias often have an insidious onset. Only gradually do white blood cells or their precursors begin to proliferate uncontrollably in the bone marrow, where they disrupt normal blood formation and migrate to the spleen, liver and other organs.
The most common type of blood cancer in adults, chronic lymphocytic leukaemia (CLL), has a known precursor: monoclonal B-cell lymphocytosis (MBL). Almost every case of CLL can be traced back to such lymphocytosis. Conversely, however, only one to two per cent of patients with lymphocytosis go on to develop leukaemia each year.
An international team of researchers has now investigated the link between the two conditions using data from 23 patients with lymphocytosis, five of whom later developed leukaemia. The findings suggest that a chemical signature in the DNA characteristic of cancer is already present in the very earliest stages of lymphocytosis. The typical changes (alterations in methylation patterns) to the genetic material remain stable throughout the entire period and persist even after successful cancer treatment. “It appears that the course of the cancer is set at an extremely early stage, and the characteristic chemical changes in the DNA could therefore be a prerequisite and a driver for the development of the cancer,” the researchers speculate.
This has no immediate implications for treatment. “There will continue to be no reason to treat monoclonal B-cell lymphocytosis with conventional therapies,” say the researchers: “At this stage, treatment carries more risks than the disease itself. However, these findings could one day be incorporated into novel therapies.”
References:
Max Planck Institute, Berlin; Dana-Farber Cancer Institute, Boston
; Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy; Blood Cancer Discovery 2021; https://bloodcancerdiscov.aacrjournals.org/content/2/1/54